| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
|
N Engl J Med
|
2006
|
22.86
|
|
2
|
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
|
N Engl J Med
|
2003
|
17.23
|
|
3
|
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
|
J Clin Oncol
|
2009
|
9.40
|
|
4
|
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
|
N Engl J Med
|
2002
|
8.86
|
|
5
|
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
|
Blood
|
2006
|
6.89
|
|
6
|
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.
|
N Engl J Med
|
2003
|
4.90
|
|
7
|
High-dose daunorubicin in older patients with acute myeloid leukemia.
|
N Engl J Med
|
2009
|
4.90
|
|
8
|
Cytarabine dose for acute myeloid leukemia.
|
N Engl J Med
|
2011
|
4.15
|
|
9
|
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
|
Blood
|
2002
|
4.00
|
|
10
|
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
|
Blood
|
2002
|
3.60
|
|
11
|
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
|
Blood
|
2007
|
3.18
|
|
12
|
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.
|
J Clin Oncol
|
2011
|
3.09
|
|
13
|
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
|
Blood
|
2009
|
3.07
|
|
14
|
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia.
|
Blood
|
2007
|
2.61
|
|
15
|
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
|
Blood
|
2002
|
2.33
|
|
16
|
Human leukocyte antigen DR15 is associated with reduced relapse rate and improved survival after human leukocyte antigen-identical sibling hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2006
|
2.29
|
|
17
|
Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation.
|
Blood
|
2010
|
2.26
|
|
18
|
Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.
|
J Clin Oncol
|
2005
|
2.15
|
|
19
|
KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy.
|
Biol Blood Marrow Transplant
|
2006
|
2.10
|
|
20
|
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach.
|
Nat Rev Clin Oncol
|
2012
|
2.05
|
|
21
|
Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia.
|
Blood
|
2002
|
2.03
|
|
22
|
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
|
J Clin Oncol
|
2012
|
2.01
|
|
23
|
The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation.
|
Blood
|
2007
|
1.96
|
|
24
|
Spermatogenesis in long-term survivors after allogeneic hematopoietic stem cell transplantation is associated with age, time interval since transplantation, and apparently absence of chronic GvHD.
|
Blood
|
2006
|
1.94
|
|
25
|
Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005.
|
Biol Blood Marrow Transplant
|
2005
|
1.81
|
|
26
|
Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature.
|
Clin Infect Dis
|
2008
|
1.79
|
|
27
|
Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia.
|
Chest
|
2004
|
1.78
|
|
28
|
Severe events in donors after allogeneic hematopoietic stem cell donation.
|
Haematologica
|
2008
|
1.72
|
|
29
|
Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
|
Blood
|
2006
|
1.67
|
|
30
|
Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation.
|
Blood
|
2007
|
1.67
|
|
31
|
Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases.
|
Haematologica
|
2009
|
1.65
|
|
32
|
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.
|
Blood
|
2005
|
1.63
|
|
33
|
Impact of HLA-DPB1 haplotypes on outcome of 10/10 matched unrelated hematopoietic stem cell donor transplants depends on MHC-linked microsatellite polymorphisms.
|
Biol Blood Marrow Transplant
|
2011
|
1.63
|
|
34
|
Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.
|
J Clin Oncol
|
2012
|
1.60
|
|
35
|
Validation of the EBMT risk score in chronic myeloid leukemia in Brazil and allogeneic transplant outcome.
|
Haematologica
|
2005
|
1.50
|
|
36
|
Association of TNFd and IL-10 polymorphisms with mortality in unrelated hematopoietic stem cell transplantation.
|
Transplantation
|
2006
|
1.49
|
|
37
|
Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease.
|
Lancet
|
2002
|
1.49
|
|
38
|
The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders.
|
Haematologica
|
2008
|
1.45
|
|
39
|
Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT).
|
Haematologica
|
2005
|
1.45
|
|
40
|
Initial cord blood unit volume affects mononuclear cell and CD34+ cell-processing efficiency in a non-linear fashion.
|
Cytotherapy
|
2011
|
1.43
|
|
41
|
NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities.
|
Blood
|
2007
|
1.40
|
|
42
|
Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group.
|
Haematologica
|
2007
|
1.39
|
|
43
|
Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation.
|
Haematologica
|
2009
|
1.34
|
|
44
|
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
|
Blood
|
2004
|
1.33
|
|
45
|
Bone marrow examination: a prospective survey on factors associated with pain.
|
Ann Hematol
|
2010
|
1.27
|
|
46
|
Autologous stem cell transplantation for systemic lupus erythematosus.
|
Lupus
|
2004
|
1.24
|
|
47
|
Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse.
|
Biol Blood Marrow Transplant
|
2009
|
1.23
|
|
48
|
Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2010
|
1.21
|
|
49
|
Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial.
|
Haematologica
|
2005
|
1.21
|
|
50
|
Influence of donor/recipient sex matching on outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia.
|
Transplantation
|
2006
|
1.21
|
|
51
|
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT.
|
Blood
|
2005
|
1.18
|
|
52
|
Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial.
|
Br J Haematol
|
2005
|
1.14
|
|
53
|
Monoclonal T-cell expansions in asymptomatic individuals and in patients with large granular leukemia consist of cytotoxic effector T cells expressing the activating CD94:NKG2C/E and NKD2D killer cell receptors.
|
Blood
|
2002
|
1.11
|
|
54
|
Vascular endothelium as 'novel' target of graft-versus-host disease.
|
Best Pract Res Clin Haematol
|
2008
|
1.10
|
|
55
|
Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
|
Haematologica
|
2008
|
1.08
|
|
56
|
Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
|
Cytotherapy
|
2010
|
1.07
|
|
57
|
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study.
|
Blood
|
2010
|
1.07
|
|
58
|
Quality-adjusted survival analysis shows differences in outcome after immunosuppression or bone marrow transplantation in aplastic anemia.
|
Ann Hematol
|
2004
|
1.07
|
|
59
|
The effect of prior exposure to imatinib on transplant-related mortality.
|
Haematologica
|
2006
|
1.05
|
|
60
|
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.
|
Haematologica
|
2010
|
1.05
|
|
61
|
Late pulmonary, cardiovascular, and renal complications after hematopoietic stem cell transplantation and recommended screening practices.
|
Hematology Am Soc Hematol Educ Program
|
2008
|
1.05
|
|
62
|
BAL neutrophils, serum procalcitonin, and C-reactive protein to predict bacterial infection in the immunocompromised host.
|
Chest
|
2007
|
1.03
|
|
63
|
Cutaneous graft-versus-host disease: a guide for the dermatologist.
|
Dermatology
|
2008
|
1.03
|
|
64
|
The European LeukemiaNet: achievements and perspectives.
|
Haematologica
|
2010
|
1.02
|
|
65
|
Autologous peripheral blood stem cell transplantation for acute myeloid leukemia.
|
Blood
|
2011
|
1.01
|
|
66
|
Cellular senescence of white blood cells in very long-term survivors after allogeneic hematopoietic stem cell transplantation: the role of chronic graft-versus-host disease and female donor sex.
|
Blood
|
2009
|
1.00
|
|
67
|
Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies.
|
Muscle Nerve
|
2003
|
1.00
|
|
68
|
Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation.
|
Blood
|
2010
|
0.99
|
|
69
|
Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose.
|
Blood
|
2002
|
0.99
|
|
70
|
Adult stem cell transplantation in autoimmune disease.
|
Curr Opin Hematol
|
2009
|
0.99
|
|
71
|
Reconstitution of dendritic and natural killer-cell subsets after allogeneic stem cell transplantation: effects of endogenous flt3 ligand.
|
Blood
|
2004
|
0.99
|
|
72
|
Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
|
Br J Haematol
|
2009
|
0.96
|
|
73
|
Octenidine hydrochloride for the care of central venous catheter insertion sites in severely immunocompromised patients.
|
Infect Control Hosp Epidemiol
|
2005
|
0.95
|
|
74
|
ABO blood group-incompatible living donor kidney transplantation: a prospective, single-centre analysis including serial protocol biopsies.
|
Nephrol Dial Transplant
|
2008
|
0.94
|
|
75
|
Haematopoietic stem cell transplantation for vasculitis including Behcet's disease and polychondritis: a retrospective analysis of patients recorded in the European Bone Marrow Transplantation and European League Against Rheumatism databases and a review of the literature.
|
Ann Rheum Dis
|
2006
|
0.94
|
|
76
|
Late altered organ function in very long-term survivors after allogeneic hematopoietic stem cell transplantation: a paired comparison with their HLA-identical sibling donor.
|
Haematologica
|
2010
|
0.93
|
|
77
|
High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia.
|
Blood
|
2002
|
0.91
|
|
78
|
Role of primacy of birth in HLA-identical sibling transplantation.
|
Blood
|
2007
|
0.91
|
|
79
|
Attitudes of Swiss mothers toward unrelated umbilical cord blood banking 6 months after donation.
|
Transfusion
|
2003
|
0.90
|
|
80
|
Plasticity after allogeneic hematopoietic stem cell transplantation.
|
Biol Chem
|
2008
|
0.89
|
|
81
|
A survey on cellular and engineered tissue therapies in europe in 2008.
|
Tissue Eng Part A
|
2010
|
0.88
|
|
82
|
Donor characteristics affecting graft failure, graft-versus-host disease, and survival after unrelated donor transplantation with reduced-intensity conditioning for hematologic malignancies.
|
Biol Blood Marrow Transplant
|
2011
|
0.87
|
|
83
|
Pulmonary infections diagnosed by BAL: a 12-year experience in 1066 immunocompromised patients.
|
Respir Med
|
2006
|
0.87
|
|
84
|
Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia.
|
Haematologica
|
2010
|
0.87
|
|
85
|
Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components.
|
Transfusion
|
2012
|
0.86
|
|
86
|
Clinical stem-cell sources contain CD8+CD3+ T-cell receptor-negative cells that facilitate bone marrow repopulation with hematopoietic stem cells.
|
Blood
|
2007
|
0.85
|
|
87
|
Leukocyte count and risk of thrombosis in patients undergoing haematopoietic stem cell transplantation or intensive chemotherapy.
|
Thromb Haemost
|
2010
|
0.84
|
|
88
|
Mannose-binding lectin levels and major infections in a cohort of very long-term survivors after allogeneic stem cell transplantation.
|
Haematologica
|
2010
|
0.83
|
|
89
|
Lung resection in hematologic patients with pulmonary invasive fungal disease.
|
Chest
|
2012
|
0.83
|
|
90
|
Large granular lymphocyte expansion after allogeneic hematopoietic stem cell transplant is associated with a cytomegalovirus reactivation and shows an indolent outcome.
|
Biol Blood Marrow Transplant
|
2012
|
0.83
|
|
91
|
Pathogen-inactivation of platelet components with the INTERCEPT Blood System ™: a cohort study.
|
Transfus Apher Sci
|
2011
|
0.82
|
|
92
|
Human acute myeloid leukemia CD34+CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells.
|
Haematologica
|
2009
|
0.82
|
|
93
|
Physical and not mental health is impaired in very long-term survivors after HSCT compared with their respective donors: a paired analysis.
|
Blood
|
2008
|
0.82
|
|
94
|
Effect of beta-blockers, Ca2+ antagonists, and benzodiazepines on bleeding incidence in patients with chemotherapy induced thrombocytopenia.
|
Platelets
|
2010
|
0.82
|
|
95
|
Target populations in allogeneic hematopoietic cell transplantation for autoimmune diseases--a workshop accompanying: cellular therapy for treatment of autoimmune diseases, basic science and clinical studies, including new developments in hematopoietic and mesenchymal stem cell therapy.
|
Biol Blood Marrow Transplant
|
2006
|
0.81
|
|
96
|
No evidence of plasticity in hair follicles of recipients after allogeneic hematopoietic stem cell transplantation.
|
Exp Hematol
|
2005
|
0.81
|
|
97
|
Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy.
|
J Peripher Nerv Syst
|
2009
|
0.80
|
|
98
|
Hypervariability of biofilm formation and oxacillin resistance in a Staphylococcus epidermidis strain causing persistent severe infection in an immunocompromised patient.
|
J Clin Microbiol
|
2010
|
0.80
|
|
99
|
Trends of hematopoietic stem cell transplantation in the Eastern Mediterranean region, 1984-2007.
|
Biol Blood Marrow Transplant
|
2011
|
0.80
|
|
100
|
Leukemic cluster growth in culture is an independent risk factor for acute myeloid leukemia and short survival in patients with myelodysplastic syndrome.
|
Acta Haematol
|
2008
|
0.80
|
|
101
|
Optimizing investigator-led oncology research in Europe.
|
Haematologica
|
2012
|
0.80
|
|
102
|
Birth order and outcome after HLA-identical sibling donor transplantation.
|
Blood
|
2009
|
0.79
|
|
103
|
Complete remission of alopecia universalis after allogeneic hematopoietic stem cell transplantation.
|
Blood
|
2004
|
0.79
|
|
104
|
Rituximab in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine (SAKK 31/98).
|
Haematologica
|
2008
|
0.79
|
|
105
|
The use of high dose immunoablative therapy with hematopoietic stem cell support therapy in the treatment of severe autoimmune diseases.
|
Int J Hematol
|
2002
|
0.79
|
|
106
|
Patient and product factors affecting platelet transfusion results.
|
Transfusion
|
2008
|
0.79
|
|
107
|
Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2009
|
0.79
|
|
108
|
Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries.
|
Swiss Med Wkly
|
2013
|
0.78
|
|
109
|
Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia.
|
J Cancer Res Clin Oncol
|
2014
|
0.78
|
|
110
|
Prospective change control analysis of transfer of platelet concentrate production from a specialized stem cell transplantation unit to a blood transfusion center.
|
J Clin Apher
|
2012
|
0.78
|
|
111
|
Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia.
|
Hum Pathol
|
2005
|
0.78
|
|
112
|
Oral health risks associated with HLA-types of patients undergoing hematopoietic stem cell transplantation.
|
Eur J Haematol
|
2007
|
0.78
|
|
113
|
Organ donation: Stricter management of organ transplants.
|
Nature
|
2012
|
0.78
|
|
114
|
Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins.
|
Haematologica
|
2009
|
0.77
|
|
115
|
The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes.
|
Haematologica
|
2006
|
0.77
|
|
116
|
Hematopoietic stem cell transplantation in Switzerland: a comprehensive quality control report on centre effect.
|
Swiss Med Wkly
|
2010
|
0.77
|
|
117
|
Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT).
|
Br J Haematol
|
2002
|
0.77
|
|
118
|
Fatal myocardial infarction during nilotinib treatment in a 60-year-old male patient.
|
Acta Oncol
|
2010
|
0.77
|
|
119
|
Aplastic anemia and concomitant autoimmune diseases.
|
Ann Hematol
|
2009
|
0.76
|
|
120
|
Forty years of haematopoietic stem cell transplantation: a review of the Basel experience.
|
Swiss Med Wkly
|
2014
|
0.76
|
|
121
|
Progenitor cell therapy for sacral pressure sore: a pilot study with a novel human chronic wound model.
|
Stem Cell Res Ther
|
2014
|
0.76
|
|
122
|
Persistence of recipient-type endothelium after allogeneic hematopoietic stem cell transplantation.
|
Haematologica
|
2010
|
0.75
|
|
123
|
Allogeneic hematopoietic stem-cell transplantation for myeloma: it's time for the appropriate studies.
|
J Clin Oncol
|
2011
|
0.75
|
|
124
|
JACIE celebrates its 10-year anniversary with the demonstration of improved clinical outcome.
|
Cytotherapy
|
2011
|
0.75
|
|
125
|
Determination of the donor:host blood cell ratio after haematological stem cell transplant by means of semiquantitative detection of short tandem repeat polymorphisms.
|
Swiss Med Wkly
|
2002
|
0.75
|
|
126
|
Cyclosporine-responsive thrombocytopenia in a patient with chloramphenicol-associated myelodysplastic syndrome.
|
Eur J Haematol
|
2006
|
0.75
|
|
127
|
Minimal T-cell requirements for triggering haemophagocytosis associated with Epstein-Barr virus-driven B-cell proliferation: a clinical case study.
|
Ann Rheum Dis
|
2011
|
0.75
|
|
128
|
Rate of false-positive results for threshold shifts during initial treatment with aminoglycosides.
|
ORL J Otorhinolaryngol Relat Spec
|
2004
|
0.75
|
|
129
|
Low dose 2-chlorodeoxyadenosine given as a single subcutaneous injection in patients with hairy cell leukemia: a multicentre trial SAKK 32/95.
|
Leuk Lymphoma
|
2009
|
0.75
|
|
130
|
DV-ICE, intensive induction and early transplantation for adult patients with acute lymphoblastic leukemia: a phase II study.
|
Eur J Haematol
|
2009
|
0.75
|
|
131
|
Hematopoietic progenitor cell colony growth differentiates chronic myelomonocytic leukemia from reactive monocytosis.
|
Eur J Haematol
|
2008
|
0.75
|
|
132
|
Dominant Epstein-Barr virus-specific T-cell responses are maintained during moderate and intense immunosuppressive treatment.
|
Ann Rheum Dis
|
2010
|
0.75
|
|
133
|
Role of allogeneic transplantation in chronic myeloid leukemia.
|
Expert Rev Hematol
|
2008
|
0.75
|
|
134
|
The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase.
|
Br J Haematol
|
2002
|
0.75
|
|
135
|
Platelet refractoriness due to combined anti-HLA and anti-HPA-5a alloantibodies: clinical management during myeloablative allogeneic HSCT and development of a quantitative MAIPA assay.
|
Br J Haematol
|
2007
|
0.75
|
|
136
|
Cytopenia and hematopoietic recovery after low intensity conditioning transplants.
|
Croat Med J
|
2004
|
0.75
|
|
137
|
Hematopoietic stem cell transplantation in Europe. Differences between Eastern and Western countries.
|
Hematology
|
2012
|
0.75
|
|
138
|
Relapse risk assessment of transplantation for patients with chronic myeloid leukaemia.
|
Chin Med J (Engl)
|
2003
|
0.75
|
|
139
|
Infection prevention strategies in a stem cell transplant unit: impact of change of care in isolation practice and routine use of high dose intravenous immunoglobulins on infectious complications and transplant related mortality.
|
Eur J Haematol
|
2009
|
0.75
|